The urgency behind the new assays is difficult to overstate. Since its first detection in January 2022, highly pathogenic avian influenza H5 has infected more than 13,000 wild birds and roughly 173 million poultry, with economic losses estimated between 14 and 164 billion dollars. In March 2024, an unprecedented spillover of clade 2.3.4.4b A(H5N1) into dairy cattle was reported in Texas, and the virus has since spread across 17 US states, infecting more than 1,000 cattle herds with sustained mammalian transmission and 70 human cases reported as of June 3, 2025. Historically, HPAI outbreaks such as H5N1 in Hong Kong in 1997 and H7N9 in China in 2013 have produced case fatality rates of at least 30 percent in humans, underscoring the pandemic potential that hangs over every new host adaptation.

Current diagnostic approaches each carry trade-offs that limit their usefulness in the field. Virus isolation remains the gold standard but is confined to biosafety level-3 laboratories staffed by highly trained personnel. Rapid immunoassays deliver results in about 15 minutes but suffer from reduced sensitivity and cannot discriminate between viral clades. Reverse transcription PCR offers high sensitivity and adaptability yet depends on thermocycling equipment and skilled operators, while next-generation sequencing provides nucleotide-level resolution at the cost of high expense and long turnaround times. The result, the authors argue, is a diagnostic landscape in which the tools that respond fastest to outbreaks are either too insensitive or too infrastructure-dependent to support surveillance at farms, markets, and rural clinics where spillovers first emerge.

To close this gap, the team turned to SHINE, short for Streamlined Highlighting of Infections to Navigate Epidemics, a one-pot CRISPR diagnostic platform previously developed for SARS-CoV-2 and influenza detection. In the avian influenza version of the workflow, viral RNA undergoes reverse transcription, recombinase polymerase amplification, and T7 transcription within a single tube, generating RNA amplicons that activate the collateral cleavage activity of the Cas13a enzyme when they base-pair with a complementary CRISPR RNA guide. Activated Cas13a then cuts RNA reporters, producing either a fluorescent signal read out on a plate reader or a colorimetric band on a paper lateral flow strip, the latter requiring nothing more sophisticated than a smartphone camera to document.

Assay design leaned heavily on machine learning. The researchers used ADAPT, a software platform that predicts sensitive and specific Cas13 guide sequences, to select primer and crRNA sets targeting the hemagglutinin gene segment that uniquely defines H5 viruses. Two candidate designs achieved predicted coverage of 98.72 and 96.18 percent of aligned H5N1 sequences, and the top-performing guide, targeting nucleotides 847 to 874 of the H5 consensus, was carried forward. A series of optimization experiments followed: the team tuned the ratio of T7-attached to non-T7-attached forward primers, settled on a 1:3 ratio that reduces competition between amplification and detection, increased RPA primer concentrations, and adjusted reporter, RNase H, and magnesium levels. The resulting optimized assay, SHINE-H5, reliably detected synthetic RNA targets across all tested concentrations within 60 minutes, a substantial improvement over the prototype.

Analytical characterization of SHINE-H5 was rigorous. Testing against six vaccine-derived viral seedstocks from the CDC showed high fluorescence for the intended target and negligible signal for non-target viruses. Clinical specificity was evaluated using 64 nasopharyngeal swab specimens from Massachusetts General Hospital that tested positive for seasonal influenza A or B but negative for avian H5 by qPCR; SHINE-H5 correctly returned negative results for all 64 samples, covering infections with H1N1, H3N2, and influenza B, including co-infections. The limit of detection, established with serial dilutions of H5N1 viral seedstock in viral transport media and a logistic regression model requiring at least 95 percent detection, was 121.7 copies per microliter, with a 95 percent confidence interval of 63.14 to 234.55 copies per microliter. In a head-to-head comparison, a validated RT-qPCR assay detected samples down to 10 copies per microliter while SHINE-H5 detected down to 50 copies per microliter, a sensitivity gap the authors acknowledge but one that still significantly outperforms existing H5 immunoassays.

For field deployment, the researchers adapted SHINE-H5 to a lateral flow readout, replacing the fluorescent quenched reporter with a FAM-biotin reporter whose cleavage products migrate on a paper strip. Using a larger 40-microliter reaction volume, the lateral flow version detected H5N1 seedstock down to 25 copies per microliter while retaining strong specificity against a subset of 14 seasonal influenza-positive patient samples. The team also demonstrated that the assay can detect synthetic RNA targets spiked into milk, a proof of concept for surveillance in the dairy herds now at the center of the North American outbreak.

Beyond broad H5 detection, the study introduces SHINE-H5-CS, a clade-specific assay targeting 2.3.4.4b A(H5N1), the lineage that has dominated global H5 phylogeny since 2021 and is driving the US cattle outbreak. Guide design for this assay employed BADGERS, a successor to ADAPT that integrates advanced search algorithms to explore the fitness landscape of candidate crRNAs and achieve single-nucleotide discrimination. Of three candidates, crRNA3, targeting a region of the H5 segment starting at nucleotide position 880, showed the highest on-target activity with minimal off-target signal. The researchers also shifted the forward primer four nucleotides upstream to introduce an additional mismatch that sharpened discrimination. SHINE-H5-CS consistently detected clade 2.3.4.4b RNA at concentrations above 100 copies per microliter while showing minimal cross-reactivity with non-2.3.4.4b H5 sequences and seasonal influenza seedstocks, enabling lineage identification without sequencing.

The team extended the platform to the H7 subtype, the other hemagglutinin group with well-documented potential to evolve into highly pathogenic strains. Phylogenetic analysis of 25 representative H7 strains revealed clean separation into Eurasian and North American lineages that mirror migratory bird flyways, and the 2013 Eurasian H7N9 epidemic, which caused more than 1,500 human infections with a fatality rate near 40 percent, demonstrated the public health stakes of this lineage. The resulting SHINE-H7-Eurasian assay reliably detected Eurasian H7 RNA across a range of concentrations while discriminating against North American H7 strains and a panel of unrelated seasonal influenza viruses, and it too was adapted to a lateral flow format that preserved lineage specificity.

The authors are candid about the limitations of the work. Confirmed human H5 and Eurasian H7 cases remain rare, so the assays could not be evaluated on true positive human clinical specimens, and compatibility with specimen types beyond mock milk samples, such as poultry or environmental samples, has not yet been assessed. Even so, the combination of isothermal operation at 37 degrees Celsius, turnaround times of 60 to 120 minutes, minimal instrumentation, machine-learning-accelerated assay design, and compatibility with paper-based readouts positions the SHINE family of assays as a practical bridge between laboratory-grade accuracy and point-of-need accessibility. As avian influenza continues its advance through wild birds, poultry, cattle, and occasionally people, tools that can detect not just the virus but its specific clades, close to where it emerges, may prove decisive in blunting the next spillover before it becomes the next pandemic.

Subject of Research: Development of streamlined one-pot CRISPR-Cas13 diagnostic assays for detection and genetic subtyping of H5 and H7 avian influenza viruses

Article Title: Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza

Article References: Huang, Y., Guo, A., Adams, G., Lemieux, J. E., & Myhrvold, C. (2026). Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza. iScience, 29(10), Article 117556. https://doi.org/10.1016/j.isci.2026.117556

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117556

Keywords: avian influenza, CRISPR diagnostics, SHINE assay, Cas13, H5N1, H7 avian influenza, clade 2.3.4.4b, lateral flow assay, recombinase polymerase amplification, point-of-need testing, dairy cattle outbreak, pandemic preparedness

Methylation is one of biology’s most powerful control systems. In DNA, the addition of a methyl group to the fifth position of cytosine, forming 5-methylcytosine (5mC), is catalyzed by DNA methyltransferases and governs transcriptional repression, genomic imprinting, chromatin accessibility, and cellular memory. Enzymes of the TET family further oxidize 5mC into 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine, creating a layered code of demethylation intermediates. When these patterns go awry—through hypermethylation of tumor suppressor promoters such as RASSF1A, SHOX2, and SFRP1, or global hypomethylation of repetitive elements—the result can be gene silencing, genome instability, and malignant transformation. On the RNA side, N6-methyladenosine (m6A), the most abundant internal modification in messenger RNA, dynamically regulates splicing, stability, translation, and immune recognition, while related marks such as m5C, m1A, m7G, and m3C diversify the epitranscriptomic landscape and are increasingly implicated in cancer, neurological disease, and viral infection.

Despite decades of biological insight, measuring these marks in the clinic remains stubbornly difficult. The gold standard for DNA methylation, bisulfite sequencing, relies on harsh chemical treatment that degrades DNA and destroys sequence complexity—a fatal flaw when the sample is scarce, fragmented cell-free DNA from a blood draw. Methylation-specific PCR and pyrosequencing are locus-limited, while antibody-based enrichment methods lack single-base resolution. RNA methylation detection fares worse: MeRIP-seq maps modified regions only to roughly 100-nucleotide windows, mass spectrometry offers global averages without sequence context, and the definitive single-site method, SCARLET, is so labor-intensive and low-throughput that it is essentially confined to specialist laboratories. These constraints have kept methylation biomarkers largely out of point-of-care and decentralized testing, despite their measurable presence in body fluids.

CRISPR-based biosensing offers a radical alternative. Cas12 and Cas13 effectors, the same enzymes famous for genome editing, carry collateral cleavage activities: once activated by a matching target, they indiscriminately shred nearby fluorescent reporters, generating an amplified signal within minutes. Because guide RNAs can be designed against virtually any sequence, the recognition step is programmable by design. Crucially, mechanistic studies have revealed that methylation itself modulates CRISPR activation—methylated DNA can weaken Cas12a activation relative to unmethylated DNA, and m6A can alter reverse-transcription read-through or reshape RNA structure in ways that Cas13 can detect. Coupled with cascade amplification strategies such as Cas13-to-Cas12 or Cas13-to-Csm6, these systems reach attomolar sensitivity, capable of distinguishing methylation states across both DNA and RNA substrates.

For DNA methylation, the review identifies three mechanistically distinct paradigms. Chemical-conversion approaches rewrite methylation status into sequence changes: bisulfite treatment converts unmethylated cytosines to uracil, turning methylation differences into SNP-like targets that platforms such as HOLMESv2, built on the mismatch-sensitive Cas12b, can quantitatively resolve. Gentler bisulfite-free variants, exemplified by meHOLMES, use TET oxidation followed by APOBEC3A deamination to preserve DNA integrity while achieving comparable discrimination. Restriction-enzyme strategies employ methylation-sensitive nucleases like HpaII and HhaI, or the methylation-dependent enzyme GlaI, to selectively triage templates before amplification and Cas12 readout—architectures that have detected the SEPT9 colorectal cancer biomarker in human serum at sensitivities reaching 86.4 attomolar. Most strikingly, direct methylation-responsive detection eliminates preprocessing altogether: in the CRISPR-MeDNA Test, 5mC at specific positions within the crRNA-target duplex suppresses Cas12a’s collateral cleavage, allowing amplification-free discrimination of methylated cfDNA in plasma from cancer patients and healthy controls.

Detecting oxidized cytosine derivatives presents its own challenges, since 5hmC, 5fC, and 5caC preserve normal Watson-Crick base pairing and thus evade direct sequence recognition. Current solutions rely on modification-selective enrichment: in the CAICas12a system, 5hmC-containing DNA is biotin-labeled, captured on magnetic beads, amplified by rolling-circle amplification, and then read out by Cas12a with a detection limit of 11 femtomolar. Analogous approaches for the rarer derivatives 5fC and 5caC remain largely undeveloped, representing a clear gap in the field.

RNA methylation sensing exploits an even broader repertoire of signal-conversion chemistry. Reverse-transcription-mediated Cas12a assays convert modification-dependent polymerase pausing, truncation, or misincorporation into methylation-readable cDNA signatures; the XNA-RT-Cas12a system achieves single-nucleotide m6A discrimination without chemical derivatization by exploiting the destabilizing effect of m6A on A-U pairing. Alternatively, the CRISPRm6A assay uses the enzyme MazF, which cleaves only unmethylated ACA motifs, so that m6A-protected RNA survives to trigger a Cas13a-Csm6 tandem amplification cascade—preamplification-free and single-base precise. Direct structure-based sensing is also emerging: because m6A induces local conformational rearrangements known as m6A switches, and Cas13 activation is exquisitely sensitive to target accessibility, the enzyme can function as a structure-responsive biosensor. The principle extends to m1A, whose positive charge disrupts Watson-Crick pairing and directly suppresses Cas13a collateral cleavage, and potentially to m5C and pseudouridine, though detection of these marks remains nascent.

The translational stakes are high. Commercial DNA methylation diagnostics—including Cologuard for colorectal cancer screening, EpiCheck for bladder cancer surveillance, and confirmMDx for prostate cancer—have already validated the clinical utility of methylation biomarkers, yet all depend on bisulfite chemistry, centralized laboratories, and multistep workflows. CRISPR methylation assays, by contrast, could combine programmable recognition, rapid fluorescent or lateral-flow readout, and compatibility with short cfDNA fragments in portable formats. But the review is candid about the distance remaining: nearly all reported platforms exist at proof-of-concept stage, tested on synthetic targets or limited clinical specimens, with none approved as a clinical assay. Fragmented cfDNA can sever methylation sites from the PAM sequences Cas enzymes require; PAM-relaxed Cas variants may expand coverage at the cost of specificity; and collateral-cleavage signals are notoriously sensitive to guide efficiency, reaction kinetics, and sample-matrix inhibition, complicating quantification and multiplexing.

The path forward, the authors argue, runs through engineering, standardization, and rigorous clinical validation. Near-term priorities include amplification-free detection of rare methylated molecules using more active Cas effectors and optimized guide designs; multiplexed panels combining Cas12 and Cas13 to simultaneously profile 5mC, 5hmC, m6A, and m1A; and artificial-intelligence tools, from deep-learning guide-activity predictors to AlphaFold 3 modeling of Cas-nucleic-acid complexes, to accelerate assay design. Longer term, integration with droplet microfluidics, single-cell sequencing, and Cas9-guided nanopore enrichment could push the technology toward spatially resolved and long-read epigenetic profiling. Manufacturing will demand defined quality attributes for Cas proteins, guide RNAs, and methylation-processing enzymes, along with commutable reference materials that currently do not exist—particularly for RNA standards. Regulatory planning, the review stresses, must begin early, since intended use, specimen type, and testing environment determine the evidentiary bar.

The authors conclude that CRISPR methylation detection is unlikely to replace PCR- and sequencing-based methods outright, but its greatest near-term value may lie in rapid, targeted, decentralized testing where conventional infrastructure is limited—from community clinics to low-resource settings. If the field can convert its remarkable analytical sensitivity into reproducible, scalable, and quantitatively calibrated workflows, CRISPR-based methylation sensing could finally bring the epigenome—and the epitranscriptome—into routine, minimally invasive diagnostics, turning a subtle layer of chemical biology into a practical clinical instrument for early cancer detection and precision medicine.

Subject of Research: CRISPR-based biosensing platforms for detecting DNA and RNA methylation as epigenetic diagnostic biomarkers

Article Title: CRISPR technologies for detecting DNA and RNA methylation: Mechanisms, platforms, and translational opportunities

Article References: Chen, K., Yang, B., Sang, R., Chen, W., Xiang, T., & Deng, F. (2026). CRISPR technologies for detecting DNA and RNA methylation: Mechanisms, platforms, and translational opportunities. Bioengineering & Translational Medicine, Article e70174. https://doi.org/10.1002/btm2.70174

Image Credits: AI Generated

DOI: 10.1002/btm2.70174

Keywords: CRISPR, DNA methylation, RNA methylation, m6A, Cas12a, Cas13, epigenetics, liquid biopsy, biosensors, cancer diagnostics, 5-methylcytosine, epitranscriptomics

RNA-targeting CRISPR systems, most notably those built around the Cas13 family of enzymes, have rapidly become a mainstay of functional genomics. By programming a guide RNA, researchers can direct Cas13 to bind and cleave virtually any transcript of interest, suppressing gene expression without permanently editing the genome. This makes the approach attractive both as a research tool and, increasingly, as the basis for therapeutic concepts in which a harmful RNA molecule is selectively degraded while the underlying DNA remains untouched.

Assessing whether these systems actually work, however, depends on accurate measurement of the target RNA. RT–qPCR has been the default method for decades: the enzyme reverse transcriptase copies RNA into complementary DNA, and the qPCR step then amplifies and quantifies that cDNA. If the amount of a specific transcript drops after CRISPR treatment, the resulting fluorescence curve shifts, and software converts the shift into a fold-change estimate. The technique is sensitive, cheap, and deeply embedded in laboratory practice, which is precisely why an artifact embedded within it has such broad consequences.

The new analysis shows that the very reagents used to deliver RNA-targeting CRISPR can interfere with the reverse transcription step itself. Guide RNAs, Cas13 proteins, and their associated components persist in cell lysates and can inhibit, compete with, or otherwise perturb the conversion of the target transcript into cDNA. When less cDNA is generated from the treated sample than from the untreated control, the qPCR readout interprets this as a loss of the transcript, even though the RNA molecule itself may still be present at nearly normal levels. The result is an apparent knockdown that is partly, or in some cases largely, an artifact of the measurement rather than a true biological effect.

According to the authors, this interference is pervasive across common experimental configurations, affecting multiple guide designs, delivery formats, and target transcripts. The magnitude of the distortion varies, but the direction is consistent: toward overestimating depletion. Because many published benchmarks of RNA-targeting CRISPR have relied on RT–qPCR as the primary or sole quantitative endpoint, the study suggests that a substantial body of reported knockdown efficiencies may need to be revisited. Some targets reported as strongly suppressed by Cas13 systems may in fact be only modestly affected.

The implications extend well beyond academic reproducibility. RNA-targeting CRISPR therapeutics are being developed for conditions ranging from viral infections to toxic-gene diseases, where the clinical promise rests on the ability to degrade a pathogenic transcript. If preclinical assessment of these candidates has depended on RT–qPCR values inflated by reagent interference, developers may have overestimated how much of the target RNA is actually removed in treated tissues. That, in turn, could alter dose predictions, safety calculations, and expectations about the biological consequences of treatment.

Importantly, the researchers did not conclude that RNA-targeting CRISPR fails to work. Direct evidence from orthogonal methods indicates that Cas13 and related enzymes genuinely cleave their targets, and many well-controlled studies have documented real knockdown. The problem is one of calibration: the field’s most convenient measurement tool has been quietly distorting the scale of the effect. The authors emphasize that distinguishing true RNA depletion from measurement artifact is essential for building an accurate picture of what these systems can achieve in practice.

The study also outlines strategies for mitigating the artifact. These include purifying RNA more stringently before reverse transcription to remove interfering components, introducing exogenous controls that can reveal inhibition of the RT step, normalizing measurements against templates added after the CRISPR reaction, and cross-checking knockdown with methods that bypass reverse transcription altogether, such as RNA sequencing, northern blotting, or amplification-free detection approaches. By triangulating across methods that are susceptible to different failure modes, laboratories can arrive at estimates of knockdown that better reflect biology.

For the broader genomics community, the findings serve as a reminder that measurement artifacts can propagate invisibly through entire literatures. RT–qPCR earned its reputation through sensitivity and convenience, but those virtues depend on assumptions that new experimental workflows can quietly violate. As RNA-targeting CRISPR matures from an exciting technique into a platform for therapeutics, the study argues, the field must apply the same scrutiny to its measurements as it does to its enzymes—because an inflated number in a notebook today can become an inflated expectation in a clinic tomorrow.

To appreciate why the artifact has gone unnoticed for so long, it helps to consider the mechanics of a typical RT–qPCR workflow. In a standard experiment, cells are lysed shortly after delivery of the CRISPR machinery, and total RNA is extracted from the resulting lysate. The assumption underlying this practice is that the extraction step cleanly separates nucleic acids from everything else in the cell, delivering a purified RNA sample whose composition reflects the biology of the treated cells. The new findings show that this assumption is fragile: components introduced by the experiment itself can carry over into the reverse transcription reaction, where they exert effects that are indistinguishable, in the final fluorescence trace, from genuine transcript depletion.

Reverse transcriptase is an enzyme with well-characterized vulnerabilities. It is sensitive to reaction conditions, can be impeded by structured or highly abundant RNA species, and is readily affected by proteins, detergents, and small molecules that contaminate an RNA preparation. Guide RNAs are a particularly interesting class of potential interferent because they are deliberately introduced at high copy numbers and are chemically identical in kind to the transcripts being measured. A surplus of exogenous RNA in a lysate can alter the kinetics with which reverse transcriptase encounters and copies any given template, shifting the apparent abundance of a target even when its true concentration has not changed.

Quantitative PCR also depends on internal logic that can be quietly subverted. The technique is relative by design: a treated sample is always compared against a control, and the fold-change is computed from the difference in amplification behavior between the two. This comparative structure is powerful, but it means that any perturbation applied asymmetrically—for example, an inhibitor present only in treated samples—translates directly into an apparent change in abundance. The artifact therefore exploits the comparative nature of qPCR rather than any flaw in the chemistry of amplification itself, which helps explain why routine quality checks on the PCR step fail to flag the problem.

Historical precedent offers some comfort to those worried about the durability of the affected literature. Measurement artifacts have repeatedly reshaped molecular biology, from early issues with RNA interference reagents triggering off-target innate immune responses to the well-documented problems of antibody specificity and cell-line misidentification. In each case, the field eventually converged on validation standards—replication with independent reagents, orthogonal readouts, and reporting guidelines—that made the artifacts visible and controllable. The present study can be read as a step in that same tradition, converting a vague suspicion that something is off into a mechanistic account with concrete remedies.

The remedies themselves deserve attention because they vary in cost and rigor. Adding a spike-in control—a known quantity of exogenous RNA introduced at the lysis stage—allows a laboratory to detect whether reverse transcription is being inhibited, since inhibition will suppress the signal from the spike-in as well as from endogenous transcripts. This approach is inexpensive and can be retrofitted into existing workflows with minimal disruption. More definitive, though more demanding, is to move the measurement entirely away from reverse transcription, relying on methods that interrogate RNA directly. Each strategy intercepts the artifact at a different point, which is why the authors advocate combining them rather than treating any single fix as sufficient.

For journals and reviewers, the findings raise practical questions about editorial standards. Knockdown efficiency numbers appear in abstracts, grant applications, and regulatory filings, yet the measurement methods behind them are rarely scrutinized with the intensity applied to, say, statistical analyses. The study suggests that reporting the composition of delivery reagents, the presence of spike-in controls, and the use of at least one reverse-transcription-independent validation method should become standard practice for claims of RNA depletion. Such requirements would not eliminate the convenience of RT–qPCR but would force claims built upon it to be explicitly qualified.

There is also a conceptual lesson about the difference between a tool’s reliability and the reliability of conclusions drawn from it. RT–qPCR remains an excellent technique within its validated envelope; the artifact arises when experimental contexts push it outside that envelope in ways no individual assay reveals. This pattern—sound method, invalidated conclusion—is among the hardest failure modes in science to police, because each individual experiment looks internally consistent. Only when someone systematically varies the conditions across many experiments does the bias emerge, which is precisely the kind of cross-experimental analysis the new study performs.

Finally, the work underscores why investments in measurement science pay outsized dividends. Enzymes like Cas13 attract headlines and funding because they are novel and mechanistically elegant, yet the value of the entire enterprise rests on quantification. A modest program to characterize, standardize, and stress-test the assays used to evaluate a technology can shape the field as profoundly as improvements to the technology itself. In this case, a careful audit of a routine laboratory step may end up recalibrating a decade of reported results and sharpening the trajectory of an emerging therapeutic platform.

Subject of Research: A reverse transcription qPCR artifact that overestimates RNA knockdown by RNA-targeting CRISPR systems

Article Title: A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR

Article References: Watkins, L., Zhu, A., & Wu, B. (2026). A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03291-1

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03291-1

Keywords: RT-qPCR, RNA knockdown, CRISPR, Cas13, RNA-targeting, measurement artifact, reverse transcription, gene expression, functional genomics, RNA therapeutics, Nature Biotechnology, pervasive